Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 8Lung Neoplasms 5Colorectal Neoplasms 3Prostatic Neoplasms 2Neoplasm Metastasis 2Melanoma 2Hot Flashes 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2COVID-19 2Brain Neoplasms 2Water-Electrolyte Imbalance 1Ventilator-Induced Lung Injury 1Surgical Wound 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Severe Acute Respiratory Syndrome 1Rectal Neoplasms 1Postoperative Complications 1Pathologic Complete Response 1Neoplasm, Residual 1Mastocytosis 1Lymphopenia 1Lymphoma, Non-Hodgkin 1Lymphedema 1Lower Urinary Tract Symptoms 1Locally Advanced Head and Neck Squamous Cell Carcinoma 1Leukemia, Myeloid, Acute 1Leukemia, Hairy Cell 1Hypersensitivity 1

Interventions

Sodium Chloride 1Amiodarone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Atrial Fibrillation × Sodium Chloride × Clear all
NCT06067438 2026-05-22

Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer

OHSU Knight Cancer Institute

Phase 2 Recruiting
90 enrolled
Gastrointestinal

Atrial Fibrillation, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡